Volume 6.24 | July 3

2020-07-03 | ICN 6.24
Intestinal Cell News by STEMCELL Technologies
Vol. 6.24 – 3 July, 2020
TOP STORY

Intestinal Epithelial Expression of MHCII Determines Severity of Chemical, T Cell-Induced, and Infectious Colitis in Mice

In mice with dextran sodium sulfate or T cell-induced colitis, loss of histocompatibility complex class II (MHCII) from Intestinal epithelial cells reduced but did not eliminate mucosal inflammation. However, in mice with C rodentium-induced colitis, loss of MHCII reduced bacterial clearance by decreasing binding of IgA to commensal and pathogenic bacteria.
[Gastroenterology]

Abstract

Find the Right Antibodies For Your Stem Cell Research. Learn More
PUBLICATIONSRanked by the impact factor of the journal

Epithelial-Derived Gasdermin D Mediates Nonlytic IL-1β Release during Experimental Colitis

Scientists report a nonpyroptotic role of full-length Gasdermin D in guiding the release of IL-1β–containing small extracellular vesicles from intestinal epithelial cells .
[Journal of Clinical Investigation]

Full ArticleGraphical Abstract

SOX18 Promotes Gastric Cancer Metastasis through Transactivating MCAM and CCL7

Investigators defined a C-C motif chemokine ligand 7-CCR1-SRY-box transcription factor positive feedback loop that played a pivotal role in gastric cancer metastasis
[Oncogene]

Abstract

CDK5RAP3 as Tumor Suppressor Negatively Regulates Self-Renewal and Invasion and is Regulated by ERK1/2 Signaling in Human Gastric Cancer

Results demonstrated that CDK5 regulatory subunit-associated protein 3 was suppressed by extracellular-related kinase signalling and negatively regulated the self-renewal and epithelial-to-mesenchymal transition of gastric cancer stem-like cells.
[British Journal of Cancer]

Abstract

Reduced Replication Origin Licensing Selectively Kills Kras-Mutant Colorectal Cancer Cells via Mitotic Catastrophe

Scientists showed vulnerability of KRAS-mutant cells towards suppression of minichromosome maintenance complex component 7 and suggested that inhibiting DNA replication licensing might be a viable strategy to target KRAS-mutant cancers.
[Cell Death & Disease]

Full Article

Exosomal MiR‐500a‐3p Promotes Cisplatin Resistance and Stemness via Negatively Regulating FBXW7 in Gastric Cancer

Researchers found that microRNA‐500a‐3p was highly expressed in cisplatin resistant gastric cancer cells and their secreted exosomes than that in the corresponding parental cells.
[Journal of Cellular and Molecular Medicine]

Full Article

Deterministic Culturing of Single Cells in 3D

Scientists presented an alternate method to culture individually selected cells in relative isolation from the rest of the population under physiologically relevant matrix conditions. Using examples of breast and colorectal cancers, scientists showed that individual cells evolved into tumors or aspects of tumors displaying different characteristics of the initial cancer type and aggressiveness.
[Scientific Reports]

Full Article

NRAS Mutant E132K Identified in Young-Onset Sporadic Colorectal Cancer and the Canonical Mutants G12D and Q61K Affect Distinct Oncogenic Phenotypes

The novel NRAS mutant E132K, identified in three tumor samples from Filipino young-onset, sporadic colorectal cancer patients, was investigated for its effects on different cancer hallmarks, alongside the NRAS canonical mutants G12D and Q61K which were yet poorly characterized in the context of colorectal cancer.
[Scientific Reports]

Full Article

Find the Right Antibodies For Your Stem Cell Research. Learn More
REVIEWS

Tumor Budding and Its Clinical Implications in Gastrointestinal Cancers

The authors give an update on International Tumour Budding Consensus Conference validation studies in the context of colorectal cancer and the clinical implications of tumour budding throughout the upper gastrointestinal and pancreatico-biliary tract.
[British Journal of Cancer]

Abstract

INDUSTRY AND POLICY NEWS

Celltrion Healthcare Receives Positive CHMP Opinion for an Additional Five Indications for Remsima® SC Including for Use in Inflammatory Bowel Disease

Celltrion Healthcare announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended expanding the existing marketing authorisation for the subcutaneous formulation of Remsima® in an additional five indications: for the treatment of patients with ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriatic arthritis and psoriasis.
[Celltrion]

Press Release

United Kingdom Plans ‘Office for Talent’ to Smooth Entry for Top Scientists

The UK government plans to set up an “office for talent” to oversee visas and make it easier to attract top scientists after Brexit, according to an R&D road map.
[ScienceInsider]

Editorial

Hong Kong Universities Rattled by New Security Law

Academics in Hong Kong are facing new worries after the mainland government abruptly imposed a controversial new security law that critics say could infringe on human rights and chill academic freedom.
[ScienceInsider]

Editorial

FEATURED EVENT

ESMO World Congress on Gastrointestinal Cancer

July 1 – July 4
Virtual

> See All Events

JOB OPPORTUNITIES

Research Technician – Colorectal and Breast Cancer

University of Virginia – Charlottesville, Virginia, United States

Postdoctoral Position – Gastrointestinal Disorders

KU Leuven – Leuven, Belgium

Lab Manager – Intestinal Research

Howard Hughes Medical Institute – Chevy Chase, Maryland, United States

Research Scientist – Oncology

Gilead Sciences, Inc. – Seattle, Washington, United States

Cancer Biology Invesigator – Cancer Epigenetics

GSK – Collegeville, Pennsylvania, United States

> See All Jobs

Submit an article, publication, job or event
Brought to you by
stemcell-logo-for newsletter-2
Intestinal Cell News Twitter